Insider Selling: Tempus AI (NASDAQ:TEM) CEO Sells $49,000.00 in Stock

Tempus AI, Inc. (NASDAQ:TEM) CEO Ryan Fukushima sold 700 shares of the company’s stock in a transaction dated Wednesday, September 16th. The stock was sold at an average price of $70.00, for a total transaction of $49,000.00. Following the transaction, the chief executive officer owned 15,874 shares of the company’s stock, valued at approximately $1,111,180. This trade represents a 4.22% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ryan Fukushima also recently made the following trade(s):

• On Friday, August 21st, Ryan Fukushima sold 14,286 shares of Tempus AI stock. The stock was sold at an average price of $70.00, for a total value of $1,000,020.00.
• On Tuesday, August 18th, Ryan Fukushima sold 41,095 shares of Tempus AI stock. The stock was sold at an average price of $49.61, for a total value of $2,038,722.95.
• On Friday, August 7th, Ryan Fukushima sold 20,000 shares of Tempus AI stock. The stock was sold at an average price of $50.04, for a total value of $1,000,800.00.
• On Monday, August 3rd, Ryan Fukushima sold 23,818 shares of Tempus AI stock. The shares were sold at an average price of $46.19, for a total value of $1,100,153.42.
• On Wednesday, July 8th, Ryan Fukushima sold 33,284 shares of Tempus AI stock. The shares were sold at an average price of $57.39, for a total value of $1,910,168.76.
• On Monday, July 6th, Ryan Fukushima sold 10,000 shares of Tempus AI stock. The stock was sold at an average price of $60.00, for a total transaction of $600,000.00.

Tempus AI Price Performance

Shares of Tempus AI stock traded down $2.52 during trading hours on Friday, reaching $77.84. 9,310,212 shares of the company’s stock were exchanged, compared to its average volume of 7,226,184. Tempus AI, Inc. has a 1 year low of $40.77 and a 1 year high of $104.32. The company has a market capitalization of $14.04 billion, a P/E ratio of -54.06 and a beta of 3.72. The business has a fifty day moving average of $57.19 and a two-hundred day moving average of $52.90. The company has a quick ratio of 3.16, a current ratio of 3.30 and a debt-to-equity ratio of 3.06.

Tempus AI (NASDAQ:TEM) last issued its earnings results on Thursday, July 30th. The company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.10. The business had revenue of $382.49 million during the quarter, compared to analysts’ expectations of $379.69 million. Tempus AI had a negative net margin of 17.77% and a negative return on equity of 50.28%. The company’s quarterly revenue was up 21.6% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.22) earnings per share. As a group, research analysts predict that Tempus AI, Inc. will post -1.38 earnings per share for the current fiscal year.

Institutional Trading of Tempus AI

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Amova Asset Management Americas Inc. increased its stake in Tempus AI by 1.2% in the 4th quarter. Amova Asset Management Americas Inc. now owns 3,504,823 shares of the company’s stock valued at $206,960,000 after buying an additional 41,728 shares during the period. Sumitomo Mitsui Trust Group Inc. boosted its position in shares of Tempus AI by 23.4% in the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,326,313 shares of the company’s stock worth $195,636,000 after buying an additional 821,490 shares in the last quarter. Geode Capital Management LLC lifted its stake in Tempus AI by 8.2% in the 4th quarter. Geode Capital Management LLC now owns 1,870,510 shares of the company’s stock valued at $110,478,000 after buying an additional 141,680 shares in the last quarter. Franklin Resources Inc. boosted its stake in shares of Tempus AI by 27.9% during the fourth quarter. Franklin Resources Inc. now owns 1,861,782 shares of the company’s stock valued at $109,938,000 after acquiring an additional 405,662 shares during the last quarter. Finally, Lingotto Investment Management LLP lifted its stake in shares of Tempus AI by 45.9% during the 4th quarter. Lingotto Investment Management LLP now owns 1,143,526 shares of the company’s stock worth $67,525,000 after purchasing an additional 359,667 shares during the period. 24.22% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts have issued reports on the company. Roth Capital assumed coverage on Tempus AI in a report on Tuesday, September 8th. They issued a “neutral” rating and a $67.00 target price for the company. Cantor Fitzgerald started coverage on Tempus AI in a research note on Wednesday, September 2nd. They set an “overweight” rating and a $80.00 target price for the company. UBS Group initiated coverage on shares of Tempus AI in a research report on Wednesday, September 9th. They set a “neutral” rating and a $70.00 price objective for the company. Guggenheim raised their price objective on shares of Tempus AI from $60.00 to $65.00 and gave the company a “buy” rating in a research note on Thursday, July 16th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $75.00 target price on shares of Tempus AI in a research note on Friday, July 31st. Eleven investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, Tempus AI has an average rating of “Hold” and an average price target of $69.33.

Tempus AI News Summary

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: CEO commentary outlining Tempus AI’s growth strategy and projected Medicare revenue has strengthened confidence that reimbursement expansion could provide a significant new revenue stream. Tempus AI Stock Roars Back 92% From July Low After CEO Lays Out Growth Plan
• Positive Sentiment: Morgan Stanley’s updated outlook reportedly incorporated additional reimbursement-driven revenue potential, helping fuel a sharp weekly advance in TEM shares and reinforcing the bullish growth narrative. Tempus AI Is Ripping 30% Higher This Week After Morgan Stanley Boosts Revenue Outlook
• Positive Sentiment: Trading momentum remains strong: shares have rebounded roughly 92% to 95% from the July low, with market capitalization moving above $14 billion. Above-average volume and elevated call-option activity indicate substantial speculative interest. Tempus AI Stock Is Soaring
• Neutral Sentiment: Analysts and market commentators are assessing whether the recent surge can continue. The rally has improved sentiment, but the sharp move also raises the risk of profit-taking and increased volatility. Strength Seen in Tempus
• Negative Sentiment: Zacks cautioned that recent earnings-estimate revision trends may not support another near-term advance, while brokerages maintain an average “Hold” rating. Tempus also remains unprofitable, making the stock particularly sensitive to valuation concerns and changes in growth expectations. Tempus AI Receives Average Hold Rating

Tempus AI Company Profile

Tempus AI, Inc is a healthcare technology company focused on applying artificial intelligence and data analytics to precision medicine. The company combines molecular testing, clinical data and machine learning to help physicians make more informed treatment decisions and support the development of new therapies.

Tempus provides genomic and diagnostic testing services, including testing intended to identify clinically relevant mutations and other biomarkers. Its technology platform also organizes and analyzes clinical and molecular data, while its AI-enabled tools are designed to assist healthcare professionals with patient care, research and workflow management.

The company serves healthcare providers, patients, pharmaceutical companies and biotechnology researchers, primarily in the United States.